Japanese biopharma firm PeptiDream (TYO: 4587) saw its shares gain 3.2% to 4,505 yen after it said it had entered into a collaboration with a US pharma major.
The company revealed the signing of a technology license agreement with Eli Lilly (NYSE: LLY) to non-exclusively rights to PeptiDream’s proprietary peptide discovery platform system (PDPS) technology.
Under the terms of the accord, PeptiDream will receive upfront and annual technology access payments, and will be eligible for development milestones and royalties on future sales of products (both peptide and small molecule therapeutics) that arise from use of the PDPS technology. Similar to previous technology licenses, the license will exclude work on peptide-drug conjugate (PDC) programs, as PeptiDream has extensive internal development efforts ongoing in this area, to which PeptiDream will be providing additional information soon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze